# A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

> **NCT07723248** · PHASE3 · RECRUITING · sponsor: **ORIC Pharmaceuticals** · enrollment: 600 (estimated)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Rinzimetostat
- **DRUG:** Darolutamide
- **DRUG:** Enzalutamide
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07723248
- **Lead sponsor:** ORIC Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-03
- **Primary completion:** 2028-03
- **Final completion:** 2030-09
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723248, "A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07723248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*